Interstim Therapy Retrospective Cost Analysis and Quality of Life

MedtronicNeuro1 个研究点分布在 1 个国家目标入组 150 人开始时间: 2005年7月最近更新: 2008年7月28日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: MedtronicNeuro
入组人数: 150
试验地点: 1

研究概览入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

A study to examine the impact that Interstim Therapy for Urinary Control has on health care utilization and costs within a health care system and the satisfaction with treatment expressed by patients using this therapy.

详细描述

A retrospective administrative data analysis combined with a prospective health related quality of life/satisfaction with treatment survey designed to examine the impact that Interstim Therapy for Urinary Control has had on health care utilization and costs for the Kaiser Permanente system and the satisfaction with treatment expressed by patients using this therapy.

研究设计

研究类型: Observational

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

MedtronicNeuro

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

终止

不适用

Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral FractureFemoral Fracture

NCT01141894Karolinska Institutet150

已完成

不适用

Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional TherapyArthritis, Psoriatic, Psoriasis

NCT00303186Pfizer107

已完成

不适用

Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency AnemiaIron Deficiency Anemia (IDA)

NCT01984554American Regent, Inc.551

招募中

不适用

Cost analysis of Pre operative navigation alignment in total knee arthroplasty compared to conventional instrumentation for total knee allignment.Bloodloss, Hospitalization, Sterillisation, less instruments, storage, navigation, allignment, jigs

NL-OMON29430P Kort (MD, PhD), Orthopedic SurgeonPostaddress Department of Orthopedic Surgery, Orbis Medisch Centrumdr H vd Hoffplein 1 Address postalcode 6162 BG city Geleen country The Netherlands90

已完成

不适用

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)Breast Cancer

NCT02658461Hoffmann-La Roche36